In a small laboratory at Niigata University, Dr. Godfried Dougnon watched as neurons struggled to clear toxic debris—fragments of their own DNA spilling from damaged nuclei, clogging the cell’s interior like nuclear waste in a failing filtration system. What he and his team discovered reshapes decades of thinking about Alzheimer’s disease: the amyloid precursor protein (APP), long vilified as the source of harmful amyloid-β plaques, actually serves as a guardian of neuronal health by expelling this damaged nuclear material through a process called lysosomal exocytosis.
For years, APP has been studied almost exclusively for its role in generating amyloid-β, the sticky protein fragments that accumulate in the brains of Alzheimer’s patients. But the normal, protective functions of full-length APP have remained a mystery—until now. The Niigata team found that when neurons suffer nuclear damage from aging or stress, APP moves to the scene, binding to escaped DNA fragments and histone proteins and guiding them toward lysosomes, which then fuse with the cell membrane to eject the waste outside the cell.
Using human iPSC-derived neurons, mouse models, and postmortem brain tissue from Alzheimer’s patients, the researchers demonstrated that this cleanup system fails when APP is impaired. Neurons with reduced APP function—or those carrying familial Alzheimer’s mutations in the APP gene—could not clear nuclear debris. Instead, the waste built up inside, triggering inflammation and ultimately cell death. In mice, lowering APP levels increased DNA damage markers, while restoring normal APP reduced them. Crucially, mutant APP failed to offer the same protection.
Even more telling, analysis of human Alzheimer’s brain tissue revealed neurons packed with nuclear waste, distorted nuclei, and lower levels of APP per cell—strong evidence that this protective mechanism breaks down in the disease. The findings, published in Proceedings of the National Academy of Sciences, suggest that Alzheimer’s may not begin with amyloid plaques, but with the failure of a vital cellular cleanup process.
“This changes how we see APP entirely,” says senior author Dr. Hideaki Matsui. “It’s not just a source of toxic peptides—it’s a protector of genomic integrity.” The discovery opens new paths for understanding and potentially treating Alzheimer’s by targeting nuclear waste clearance, lysosomal function, or early DNA damage. As the global burden of dementia grows, this reframing of an old villain as a fallen hero offers not just insight, but hope.